research– category –
-
A discovery of an ALS Pathology-Inhibiting Factor ~a major step toward new therapies through Academic Collaboration~
On October 16, the latest research accomplished by the collaborative team of our CEO, Dr. Eiichiro Mori, and our scientific advisors—Dr. Tomohide Saio (Tokushima University), Dr. Kazuma Sugie (Nara Medical University), Dr. Masashi Aoki (... -
molmir and OrganoTherapeutics announce strategic R&D collaboration~ accelerate developing therapeutics for Parkinson’s disease with 3D midbrain organoids~
molmir Inc. (based in Nara, Japan, CEO: Eiichiro Mori, M.D., Ph.D.) is proud to announce that it has entered into an agreement with OrganoTherapeutics SARL (based in Esch-sur-Alzette, Luxembourg, CEO: Jens Schwamborn, Ph.D.) for R&D ...
1